Adarigiline
Adarigiline is a monoamine oxidase inhibitor that was never marketed. It is specifically a monoamine oxidase B inhibitor. This drug candidate was first described in 2009, in a patent assigned to Helicon Therapeutics.
Adarigiline is a monoamine oxidase inhibitor that was never marketed. It is specifically a monoamine oxidase B inhibitor. This drug candidate was first described in 2009, in a patent assigned to Helicon Therapeutics.